DxTerity CEO & Founder Bob Terbrueggen to speak at World CDx and Precision Medicine in Autoimmunity
DxTerity CEO & Founder Bob Terbrueggen will be speaking at two upcoming conferences in October: World CB & CDx in Boston, MA and Precision Medicine in Autoimmunity in Denver, CO.
Dr. Terbrueggen will discuss how precision medicine powered by companion diagnostics has been slow to emerge in the autoimmune disease space in large part due to the lack of new drug approvals, and how efforts are underway to change this. Unlike oncology in which companion diagnostics are largely based on DNA, autoimmune disease will rely on RNA testing and pathway analysis for therapy selection. New technology providing Type 1 Interferon status—a common diagnostic target—as well as proprietary T-cell signatures and modular expression analysis to characterize cell content and disease activity, may help stratify patients for studies and evaluate response to therapy.
Details for each event are below:
October 4-5, 2018 • World CB&CDx • Boston, MA
“Companion Diagnostics in Autoimmune Disease and SLE – RNA Testing”
Date: Conference Day Two: Friday, October 5, 2018
Time: 1PM EST
Track: Drug & Diagnostic Commercialization Track: Building the Commercial Strategy to Achieve a Global Footprint for Precision Medicines
October 10-12, 2018 • Precision Medicine in Autoimmunity • Denver, CO
“Industry Perspective: Companion Diagnostics in Autoimmune Disease and SLE – RNA Testing”
Date: Conference Day Three: Friday, October 12, 2018
Time: 1:15-1:45PM MDT
Location: The Platte River Room in the Westin Denver Downtown